LBA58_PR Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.

G. Zalcman , J. Mazieres , L. Greillier , Sylvie Lantuéjoul , P. Dô , O. Bylicki , I. Monnet , R. Corre , C. Audigier-Valette , M. Locatelli-Sanchez , O. Molinier , L. Thiberville (1, 2) , T. Urban , D. Planchard , C. Ligeza-Poisson , E. Amour , F. Morin , D. Moro-Sibilot , A. Scherpereel

1 Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen]
2 QuantIF-LITIS - Equipe Quantification en Imagerie Fonctionnelle

Domaines: Sciences du Vivant [q-bio]

G. Zalcman, J. Mazieres, L. Greillier, Sylvie Lantuéjoul, P. Dô, et al.. LBA58_PR Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.. Annals of Oncology, 2017, 28 (suppl_5,1). ⟨hal-01676481⟩